Fundamental reforms to NHI pricing anticipated
Implement proper measures to expand business and secure profitability
Three keys to success
• Core domains: infectious disease, CNS, respiratory
MRs provide medical information together with new drugs to increase presence - Fusion strategy
• Streamline the number of products
Review quality, stable supply and profitability
Consider reducing number of products
• Start importing generic drugs made at Medreich to Japan from October, 2017
• Seven products in FYE March 2018
• Expand product lineups from Medreich over time
• 3 billion tablets/year: Medreich's production capacity for the Japanese market
• Establish Me Pharma Co., Ltd. to create new business model
• Enable stable supply of low-cost, quality generics for the Japanese market
• Great opportunity for business expansion
Fundamental reforms to NHI pricing anticipated
Implement proper measures to expand business and secure profitability
Three keys to success
Product portfolio• Core domains: infectious disease, CNS, respiratory
MRs provide medical information together with new drugs to increase presence - Fusion strategy
• Streamline the number of products
Review quality, stable supply and profitability
Consider reducing number of products
Costs• Start importing generic drugs made at Medreich to Japan from October, 2017
• Seven products in FYE March 2018
• Expand product lineups from Medreich over time
Sales structure• 3 billion tablets/year: Medreich's production capacity for the Japanese market
• Establish Me Pharma Co., Ltd. to create new business model
• Enable stable supply of low-cost, quality generics for the Japanese market
• Great opportunity for business expansion